SLV-324
Solve Therapeutics Raises $120M to Advance Next-Generation ADCs for Solid Tumors
Solve Therapeutics; antibody-drug conjugates; ADC; CloakLink linker technology; solid tumors; oncology; SLV-154; SLV-324; clinical trials; venture capital; Yosemite; Merck